Antimicrobial peptide therapy for tuberculosis infections
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the tuberculosis project. A PhD thesis entitled ‘’Antimicrobial peptide therapy for tuberculosis infections’’, from the group of Professor G. Godaly, was successfully defended by Komal Umashankar Rao.Tuberculosis is a major cause of mortality in all parts of the world, not least in patients whose immune system is compromised as in HIV infected individuals. The